Investors Asset Management of Georgia Inc. GA ADV raised its holdings in shares of AstraZeneca plc (NYSE:AZN) by 1.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,315 shares of the company’s stock after acquiring an additional 300 shares during the quarter. Investors Asset Management of Georgia Inc. GA ADV’s holdings in AstraZeneca were worth $821,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Lake Point Wealth Management purchased a new stake in AstraZeneca in the 4th quarter valued at about $195,000. Mackenzie Financial Corp raised its position in shares of AstraZeneca by 311.8% during the 4th quarter. Mackenzie Financial Corp now owns 122,231 shares of the company’s stock valued at $4,642,000 after acquiring an additional 92,551 shares in the last quarter. Sit Investment Associates Inc. acquired a new stake in shares of AstraZeneca during the 4th quarter valued at approximately $171,000. Wealth Alliance Advisory Group LLC acquired a new stake in shares of AstraZeneca during the 4th quarter valued at approximately $216,000. Finally, Pinkerton Retirement Specialists LLC increased its position in AstraZeneca by 0.8% in the fourth quarter. Pinkerton Retirement Specialists LLC now owns 66,695 shares of the company’s stock worth $2,533,000 after buying an additional 536 shares during the period. 18.31% of the stock is currently owned by institutional investors and hedge funds.

Shares of AstraZeneca stock traded down $0.52 on Wednesday, hitting $38.78. 3,180,971 shares of the company’s stock were exchanged, compared to its average volume of 6,404,604. The stock has a market capitalization of $99.04 billion, a PE ratio of 11.21, a P/E/G ratio of 1.16 and a beta of 0.51. AstraZeneca plc has a 1 year low of $34.38 and a 1 year high of $43.29. The company has a debt-to-equity ratio of 1.24, a current ratio of 0.96 and a quick ratio of 0.78.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Thursday, February 14th. The company reported $1.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.85. AstraZeneca had a net margin of 9.76% and a return on equity of 32.47%. The firm had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.33 billion. During the same period last year, the firm earned $1.30 EPS. The company’s revenue was up 11.1% on a year-over-year basis. As a group, research analysts anticipate that AstraZeneca plc will post 1.79 EPS for the current year.

The company also recently disclosed a semiannual dividend, which was paid on Wednesday, March 27th. Investors of record on Friday, March 1st were paid a dividend of $0.95 per share. This represents a dividend yield of 4.64%. The ex-dividend date was Thursday, February 28th. This is a positive change from AstraZeneca’s previous semiannual dividend of $0.45. AstraZeneca’s payout ratio is 53.76%.

A number of research analysts have recently commented on the company. Zacks Investment Research raised AstraZeneca from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a report on Tuesday. UBS Group cut AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 target price for the company. in a research note on Tuesday, April 2nd. ValuEngine cut AstraZeneca from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Cowen raised AstraZeneca from a “market perform” rating to an “outperform” rating and raised their target price for the company from $42.00 to $48.00 in a research note on Monday, April 1st. Finally, Main First Bank reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, March 19th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company. AstraZeneca presently has a consensus rating of “Hold” and an average target price of $45.29.

TRADEMARK VIOLATION WARNING: “Investors Asset Management of Georgia Inc. GA ADV Has $821,000 Holdings in AstraZeneca plc (AZN)” was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/investors-asset-management-of-georgia-inc-ga-adv-has-821000-holdings-in-astrazeneca-plc-azn/2969158.html.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: No Load Funds

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.